Press Release Archives - Page 18 of 18 - Spherix Global Insights

Invest in intelligence that delivers

Press Release, Rheumatology

More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter

October 8, 2018

Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent

September 27, 2018

Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

September 21, 2018

From: Multiple Sclerosis News Today By: Alice Melao

Ocrevus Predicted to Be a Billion-dollar Blockbuster

September 4, 2018

From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical

Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On

May 31, 2018

The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but

TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population

May 30, 2018

According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors,

Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights

April 9, 2018

Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to

US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt

November 30, 2017

According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than

Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis

November 29, 2017

According to Spherix Global Insights’ latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is

Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win

November 21, 2017

According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of

Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US

November 21, 2017

EU5 adoption of Pfizer’s Xeljanz and Eli Lilly’s Olumiant has been largely limited to rheumatologists practicing in Germany, according to

Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA’s Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosis

November 21, 2017

European neurologists predict substantial uptake of Roche’s Ocrevus among primary progressive multiple sclerosis patients driven by favorable market access status

Invest in intelligence that delivers

More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

Ocrevus Predicted to Be a Billion-dollar Blockbuster

Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On

TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population

Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights

US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt

Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis

Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win

Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US

Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA’s Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosis

Download our publication plan

Visit our portal for the searchable format

©2025 Spherix. All Rights Reserved.

Site Map